Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
No open-market purchase by an insider of Halozyme was filed in the last 90 days. The latest on record was on Mar 19, 2020.
How often do Halozyme insiders buy and sell shares?
Since 2006, Halozyme insiders reported 115 open-market purchases and 1,549 sales on Forms 4 and 5, with purchases in 9 different years, most recently 2020.
Who is selling Halozyme stock?
In the last 90 days, 2 insiders of Halozyme (HALO) reported 39 open-market sales worth $22.1M in total on SEC Form 4. The largest seller by value was Helen Torley, with $19M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade HALO?
Yes. Members of Congress disclosed 2 trades in Halozyme (HALO) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent is from Rep. Gilbert Ray Cisneros Jr. (CA31).
When does Halozyme report its next results?
Halozyme's next results are expected on Jan 26, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+32.4% (+$22.79) from Nov 19, 2025 to Nov 19, 2026 · adjusted daily closes
Adjusted close went from $70.25 on Nov 19, 2025 to $93.04 on Nov 19, 2026 (+32.4%). Disclosed in this range: 3 insider trades, 105 pre-arranged insider sales, 2 Congress trades, and 44 13F position changes for 4 quarters ending in it.
$40$60$80$120$140$93.04
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 110 trades in this range as a list
Matthew L. Posard, Director · 2 pre-arranged insider sales, about $482Ktraded Nov 18, 2026, filed Nov 18, 2026
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biotechnology company based in San Diego, California.
Last 12 months
+32.4%
S&P 500 +8.0% over the same dates
Market value
$10.6B
Close of Nov 19, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 13.7M shares sold short (12.0% of shares outstanding), 0.0% vs the previous count, 6.8 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Several sources, same direction
Halozyme: 1 fund cut or exited a position in the latest available 13F filings and 1 member of Congress disclosed sales. 2 of 3 tracked groups show selling activity. Based on public disclosures; it does not say why, or what happens next. Our test of this pattern
Latest results: quarter ending Sep 30, 2026
Revenue
$493M
+39.2% vs the same quarter a year earlier
Free cash flow, last 12 months
$886M
This quarter $255M, a year earlier $176M
Net debt
$2.22B
Debt $3.25B, cash $1.03B, at Sep 30, 2026
Net income, last 12 months
$485M
Operating profit covers interest 30.6x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 5, 2026.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Last 30 days
Written by software from the filings listed below · Oct 26, 2026
Insiders.Halozyme on OQRO: In the 30 days to Oct 26, 2026, insiders filed 0 open-market purchases and 16 open-market sales (about $7.18M, in 2 filings, by 2 people). The largest sale was Helen Torley, PRESIDENT AND CEO, about $1.31M, filed Oct 8, 2026.
4 more points, with the facts they come from, are in OQRO Pro.
Since Nov 18, 2025, HALO is up 32.7% and the index fund is up 8.5%: 24 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much HALO moves
A usual day
±1.3%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
4.5%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−15.7%Nov 6, 2026
Largest one-day rise
+20.2%Aug 7, 2026
Deepest fall of the year
−29.1%From the close of Oct 29, 2026 to Nov 19, 2026.
Days of 5% or more
8Out of 252 sessions, in either direction.
Beta 0.6(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Insider buying and selling since 2006
Insiders of Halozyme reported 115 open-market purchases and 1,549 sales since 2006; purchases in 9 different years, most recently 2020.
Year
Bought
Sold
2026
—
$49.1M103×103 trades
2025
—
$25.2M60×60 trades
2024
—
$20M50×50 trades
2023
—
$16.3M44×44 trades
2022
—
$6.45M19×19 trades
2021
—
$30.1M39×39 trades
2020
$749K3×3 trades
$11.7M19×19 trades
2019
—
$64K2×2 trades
2018
—
$61.6M36×36 trades
2015
$172K1×1 trade
$1.03M2×2 trades
2014
$669K2×2 trades
$2.05M3×3 trades
2013
$682K2×2 trades
$756K3×3 trades
2012
$21.9M15×15 trades
—
2011
$13.5M11×11 trades
—
2008
$21.4M48×48 trades
$2.91M2×2 trades
2007
$36.8M12×12 trades
$10.4M1167×1,167 trades
2006
$4.31M21×21 trades
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
When insiders usually buy
Last results
Nov 5, 2026
Within the 30 days after it, until Dec 5, 2026
Next results, expected
Jan 26, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
90%
19 of 21 insider purchases since 2012 came within 30 days after a results announcement
From Halozyme's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Halozyme's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Owners above 5%
No Schedule 13D or 13G filing on HALO over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Red flags in its filings
Mar 12
Top officer leaving
“Ramsay continues to serve as Interim CFO on July 1, 2026, he will be granted an additional 2,500 RSUs which will vest on his employment termination date and be subject to a one-year holding period from the vesting date.”
“(“the Company”) announced a transition plan in which Nicole LaBrosse, Senior Vice President, Chief Financial Officer will continue to serve as the Company’s Chief Financial Officer until the earliest of when a new chief financial officer is hired, March 30, 2026 or such earlier date determined by the Company (the “Separation Date”) and then depart to pursue a new professional opportunity.”
“The Company announced today a transition plan in which Nicole LaBrosse, Senior Vice President and Chief Financial Officer (“CFO”) will continue to serve as the Company’s CFO until the earlier of when a new chief financial officer is hired, or until March 30, 2026 (the “Separation Date”) and then depart to pursue a new professional opportunity.”
From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Late-stage clinical trials
1 active phase 3 trial and 0 active phase 2 trials led by this company, mostly in hypogonadism, male. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Halozyme filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 109 open-market sales (about $50.6M, in 24 filings, by 5 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 54 open-market sales (about $23.8M, in 15 filings). (Halozyme on OQRO)
Congress. Members of Congress filed 2 disclosures on Halozyme in the 12 months to Nov 19, 2026: 1 purchase and 1 sale, by 1 member. In the 12 months before that: 1 disclosure. The largest range: Rep. Gilbert Ray Cisneros Jr. (CA31), $1,001 to $15,000, filed Oct 12, 2026.
Funds and stakes. Fund 13F filings recorded in the 12 months show 27 new or larger positions and 17 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. ClinicalTrials.gov shows 1 study sponsored by the company updated in the period; the latest, "52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replaceme..." (Phase 3, status recruiting), was updated on Nov 6, 2026, with primary completion listed for 2028-03. FINRA short interest for HALO on the settlement date of Oct 30, 2026 was 13,650,219 shares (-0.03% on the previous report), about 6.81 days of average volume.
Company reports, price and press. Halozyme filed a Form 8-K on Sep 30, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member. The company's own opening sentence of that report reads: "On September 28, 2026, James Daly was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the 'Company'). Mr. Daly was elected to the class of directors with terms ending at the Company’s annual meeting of stockhold..."
Who holds it. 666 funds reported a stake in Halozyme in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (10.7% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (4.3% of the value reported), VANGUARD PORTFOLIO MANAGEMENT LLC (4.3% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Halozyme filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 109 open-market sales (about $50.6M, in 24 filings, by 5 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 54 open-market sales (about $23.8M, in 15 filings).
The largest sale: Helen Torley, PRESIDENT AND CEO, about $1.66M, filed Sep 12, 2026.
Congress
Members of Congress filed 2 disclosures on Halozyme in the 12 months to Nov 19, 2026: 1 purchase and 1 sale, by 1 member. In the 12 months before that: 1 disclosure.
The largest range: Rep. Gilbert Ray Cisneros Jr. (CA31), $1,001 to $15,000, filed Oct 12, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 27 new or larger positions and 17 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
ClinicalTrials.gov shows 1 study sponsored by the company updated in the period; the latest, "52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replaceme..." (Phase 3, status recruiting), was updated on Nov 6, 2026, with primary completion listed for 2028-03.
FINRA short interest for HALO on the settlement date of Oct 30, 2026 was 13,650,219 shares (-0.03% on the previous report), about 6.81 days of average volume.
In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: Soros Fund Management (new position); the largest that shrank: Bridgewater Associates (reduced, 134,877 shares). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $23.2M for its principal executive officer, and an average of $3.59M for the other named executive officers.
Company reports, price and press
Halozyme filed a Form 8-K on Sep 30, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On September 28, 2026, James Daly was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the 'Company'). Mr. Daly was elected to the class of directors with terms ending at the Company’s annual meeting of stockhold..."
Halozyme filed a Form 8-K on Aug 18, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On August 14, 2026, Dannielle Appelhans was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the 'Company'). Ms. Appelhans was elected to the class of directors with terms ending at the Company’s annual meeting o..."
Halozyme filed a Form 8-K on Jul 2, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On June 30, 2026, Halozyme Therapeutics, Inc. (the 'Company') announced an update to its senior management structure. The company also announced the departure of Cortney Caudill as the Company’s Senior Vice President, Chief Opera..."
Press coverage listed by Finnhub: "HALO Stock Hits Over 3-Month Lows, As German Court Overturns Temporary Ban On Merck’s Keytruda SC" (Yahoo, Nov 19, 2026).
Press coverage listed by Finnhub: "Halozyme Provides Update on German Preliminary Injunction Hearing" (Yahoo, Nov 19, 2026).
Press coverage listed by Finnhub: "Halozyme Therapeutics: 3 Technologies, Multiple Big Pharma Partnerships" (SeekingAlpha, Nov 19, 2026).
HALO closed at $95.80 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $122.50 to $95.80, a change of −21.8%.
Who holds it
666 funds reported a stake in Halozyme in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (10.7% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (4.3% of the value reported), VANGUARD PORTFOLIO MANAGEMENT LLC (4.3% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Fails to deliver: 101K shares (about $12.5M) were not delivered on time for settlement on Oct 23, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 54.6% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (25.9% on ATS, 28.7% with other brokers), above its 26-week average of 50.7%. Weeks of Oct 5 to Oct 30, 2026.
Week of May 4ATSOther off-exchangeFull height = all shares tradedWeek of Oct 26
Largest ATS: UBS ATS (16.4%), INTELLIGENT CROSS LLC (10.8%), LEVEL ATS (9.3%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Where the revenue comes from
Latest quarter
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 5, 2026. Quarterly reports are not audited. Read the filing
By product or service
Royalties$341M69%
+44% on the same quarter a year earlier ($236M)
Bulk rHuPH20 sales$70.6M14%
+117% on the same quarter a year earlier ($32.5M)
Proprietary product sales$55.6M11%
+6.4% on the same quarter a year earlier ($52.2M)
Device partnered product sales$11.2M2.3%
+18% on the same quarter a year earlier ($9.49M)
Sales-based milestones$7M1.4%
−65% on the same quarter a year earlier ($20M)
Device licensing and development revenue$4.64M0.9%
+16% on the same quarter a year earlier ($4M)
Upfront license and target nomination fees$3M0.6%
$0 the same quarter a year earlier
Event-based development and regulatory milestones and other fees$00.0%
$0 the same quarter a year earlier
Total revenue$493M+39%
The company also reports Product sales, net ($137M), Revenues under collaborative agreements ($14.6M), which group lines above and are not added again.
The full fiscal year ended Dec 31, 2025
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 17, 2026. Read the filing
By product or service
Royalties$868M62%
+52% on the year before ($571M)
Proprietary product sales$195M14%
+17% on the year before ($167M)
Bulk rHuPH20 sales$133M9.5%
+54% on the year before ($86.3M)
Sales-based milestones$70M5.0%
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 10,000 words.
From “Overview”, in the company's words
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology (“ENHANZE”) with our proprietary enzyme rHuPH20, our commercially validated solution is used to facilitate the subcutaneous (“SC”) delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. We license our technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with our partners’ proprietary compounds.
What the section covers (33 headings)
Overview
Roche
Janssen
Takeda
Acumen
Viatris
Merus
Skye Bioscience
Corporate
Results of Operations
Comparison of Years Ended December 31, 2025 and 2024
Comparison of Years Ended December 31, 2024 and 2023
Liquidity and Capital Resources
Long-term debt
Source: SEC EDGAR, Form 10-K filed Feb 17, 2026 and Form 10-Q filed Nov 5, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
+133% on the year before ($30M)
Device partnered product sales$48.8M3.5%
−3.4% on the year before ($50.5M)
Event-based development and regulatory milestones and other fees$47M3.4%
−35% on the year before ($72.5M)
Upfront license and target nomination fees$18.5M1.3%
−32% on the year before ($27M)
Device licensing and development revenue$16.9M1.2%
+49% on the year before ($11.3M)
Total revenue$1.4B+38%
The company also reports Product sales, net ($376M), Revenues under collaborative agreements ($152M), which group lines above and are not added again.
And 19 more headings in the filing.
Risk factors in the annual report
Latest annual report filed Feb 17, 2026, compared with the one filed Feb 18, 2025. Read the filing
New risk factors in the latest annual report (1 heading)
Workforce reduction at federal agencies and changes in U.S. trade policy, including tariffs and potential countermeasures by trading partners, could delay regulatory approval and increase our or our partners’ costs, disrupt global supply chains and have a material adverse impact on our business, financial condition, and results of operations.
Legal proceedings (Item 3)
From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our policy limits may be inadequate to fully satisfy any damage awards or settlements.
Source: SEC EDGAR, Form 10-K filed Feb 17, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.